Background and Purpose-Thrombectomy, primarily with stent retrievers with or without adjunctive aspiration, provided clinical benefit across multiple prospective randomized trials. Whether this benefit is exclusive to stent retrievers is unclear. Methods-THERAPY (The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke; NCT01429350) was an international, multicenter, prospective, randomized (1:1), open label, blinded end point evaluation, concurrent controlled clinical trial of aspiration thrombectomy after intravenous alteplase (IAT) administration compared with intravenous-alteplase alone in patients with large vessel ischemic stroke because of a thrombus length of ≥8 mm. The primary efficacy end point was the percent of patients achieving independence at 90 days (modified Rankin Scale score, 0-2; intention-to-treat analysis). The primary safety end point was the rate of severe adverse events (SAEs) by 90 days (as treated analysis). Patients were randomized 1:1 across 36 centers in 2 countries (United States and Germany). Results-Enrollment was halted after 108 (55 IAT and 53 intravenous) patients (of 692 planned) because of external evidence of the added benefit of endovascular therapy to intravenous-alteplase alone. Functional independence was achieved in 38% IAT and 30% intravenous intention-to-treat groups (P=0.52). Intention-to-treat ordinal modified Rankin Scale odds ratio was 1.76 (95% confidence interval, 0.86-3.59; P=0.12) in favor of IAT. Secondary efficacy analyses all demonstrated a consistent direction of effect toward benefit of IAT. No differences in symptomatic intracranial hemorrhage rates (9.3% IAT versus 9.7% intravenous, P=1.0) or 90-day mortality (IAT: 12% versus intravenous: 23.9%, P=0.18) were observed. Conclusions-THERAPY did not achieve its primary end point in this underpowered sample. Directions of effect for all prespecified outcomes were both internally and externally consistent toward benefit. It is possible that an alternate method of thrombectomy, primary aspiration, will benefit selected patients harboring large vessel occlusions. Further study on this topic is indicated. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01429350.
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September 2016 U ntil recently, intravenous alteplase was the only proven reperfusion therapy for ischemic stroke. [1] [2] [3] [4] [5] Five consecutive, prospective, randomized thrombectomy trials have now demonstrated clinical superiority of endovascular therapy to intravenous alteplase alone or best medical care. [6] [7] [8] [9] [10] THERAPY (The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke) was designed to evaluate the potential benefit of aspiration thrombectomy for large vessel occlusion patients compared with intravenous tissue-type plasminogen activator (tPA) alone in selected patients. THERAPY hypothesized that aspiration thrombectomy would improve clinical outcomes in intravenous tPA-eligible patients with large vessel occlusion and large clot burden. THERAPY differed from contemporaneous trials in 3 critical ways: (1) thrombectomy was to be achieved by aspiration, whereas all other trials used primarily or exclusively stent retriever thrombectomy, with or without adjunctive aspiration; (2) THERAPY sought to identify the poorest prognosis patients, namely those with a clot burden of ≥8 mm; and (3) 8, 9 or multiphase computed tomographic (CT) angiography (CTA). 7 Single-arm studies have shown aspiration-based thrombectomy to safely facilitate rapid reperfusion in large vessel occlusion stroke patients. [11] [12] [13] [14] [15] Local aspiration may play an important role when used with stent retrievers for thrombectomy. 16 A fundamental question surrounding the recent overwhelming evidence supporting thrombectomy is whether this benefit is exclusive to stent retrievers as the primary approach or may result from other approaches. THERAPY, by testing aspiration thrombectomy, was uniquely positioned to provide insight into this question but was ultimately underpowered.
Materials and Methods

Study Design
THERAPY (NCT01429350) was an international, multicenter, prospective, randomized, open label, blinded end point evaluation, concurrent controlled clinical trial of aspiration thrombectomy after intravenous-alteplase administration compared with intravenousalteplase alone in patients with large vessel ischemic stroke because of ≥8 mm thrombus (the full study protocol is provided in the Materials section in the online-only Data Supplement). CT angiography was required to confirm intracranial occlusion and to rule out tandem cervical occlusion that would prevent thrombectomy without treatment. THERAPY was US Food and Drug Administration-approved and each enrolling site obtained appropriate Institutional Review Board or ethics committee approval.
Patients
Eligible patients (18-85 years old) with intracranial internal carotid artery (ICA) or middle cerebral artery occlusion on CT angiography and an National Institute of Health Stroke Scale (NIHSS) score of ≥8 were treated with intravenous-alteplase based on standard eligibility criteria. Enrollment required a nonenhanced thin-section (≤2.5 mm) CT scan demonstrating ≥8 mm clot length. Investigators were trained on clot length identification methodology 17 and each site submitted examples before study initiation. Major exclusion criteria included >1 of 3 of the affected middle cerebral artery territory with established infarction, cervical ICA stenosis/occlusion requiring treatment before thrombectomy, and prestroke disability (modified Rankin Scale [mRS] score >1). Remaining criteria are outlined in the protocol (Materials section in the online-only Data Supplement). Written informed consent was obtained from all enrolled patients.
Randomization and Masking
Patients were randomized 1:1 to either (1) intravenous-alteplase alone (intravenous group) or (2) intravenous alteplase plus aspiration thrombectomy (intravenous alteplase plus thrombectomy [IAT] group) and stratified according to enrolling center. Both the groups received full dose of intravenous-alteplase (0.9 mg/kg). Randomization was performed through a centralized interactive voice response system.
Procedures
Aspiration thrombectomy was performed with the Penumbra System and included the 3-dimensional (3D) Separator as of December 2012 and the larger bore ACE aspiration catheter as of August 2013. The use of conscious sedation versus general anesthesia and postprocedural neurocritical care was left to the treating physician's discretion.
Outcomes
The primary efficacy end point was the proportion of patients achieving functional independence by 90 days, defined as mRS score of 0 to 2, in intention-to-treat (ITT) analysis. The primary outcome measure (90-day mRS) was assessed by independent blinded adjudicators (R.E. or E.B.R.). Adjudicators reviewed videotapes of assessments performed by blinded, trained, and certified local investigators. To minimize variability, local investigators performed mRS assessment using the Rankin Focused Assessment Tool. 18 Secondary efficacy outcomes included (1) the severity of 90-day disability according to the distribution of scores across the mRS (shift analysis), (2) the proportion of patients with improvement defined as mRS score of 0 to 2 at 30 days, ≥10 point NIHSS improvement from baseline to 24 hours, or NIHSS 0 to 1 at discharge, 19 and (3) 24 hours of infarct volume measured using the Alberta Stroke Program Early CT Score (ASPECTS) and 24 hours of infarct volume worsening. 20 Patients without 90-day mRS data were excluded from primary analyses with additional sensitivity analysis assigning mRS score of 6 (death) to those patients. Efficacy analyses were prespecified for both ITT and per-protocol (PP) population.
The primary safety outcome was the incidence of 90-day serious adverse events (SAEs; see Definitions in the online-only Data Supplement for SAE definition) in an as-treated analysis. Secondary safety outcomes included the rate of symptomatic intracranial hemorrhage (sICH) and mortality at 90 days. sICH was defined as any new hemorrhage identified by the core laboratory with a concomitant ≥4 point worsening in NIHSS as recorded by a blinded, NIHSS-certified assessor.
All baseline and follow-up brain and vessel images and imaging outcome events were assessed by an independent, blinded neuroradiologist (A.Y.). The modified thrombolysis in cerebral ischemia scale 21 was used to assess angiographic reperfusion status. ASPECTS was used to evaluate for baseline ischemic change on enrollment CT scans and 24 hours of infarct volume.
20,22
Statistical Analysis
A sample size of 692 patients was calculated based on a 2-sided χ 2 test, with 80% power, an α value of 0.05, and an expected absolute difference in the 90-day mRS score of 0 to 2 rate of 10.6% between the intravenous-alteplase (24.4%) and IAT cohorts (35%). The 24.4% intravenous group estimate was based on a previous estimate of functional independence in intravenous-alteplase-treated patients with persistent large vessel occlusions. 23 The 35% rate for the thrombectomy cohort was based on intravenous-alteplase-treated patients with persistent large vessel occlusion treated with IAT in the Penumbra 
Role of the Funding Source
The trial was funded by Penumbra, Inc and designed and led by the steering committee of 5 academic investigators and 2 sponsor representatives. Site investigators gathered study data, with monitoring and database management by the sponsor. The study was monitored by an independent Data Safety and Monitoring Board (DSMB) and Clinical Events Committee (CEC). After termination of the trial, the academic investigators had unrestricted access to the data and led data analyses performed by the study statistician, who was employed by Penumbra Inc. Initial and subsequent drafts of the article were written by the academic steering committee, with input from all coauthors.
Results
Study Termination
Trial enrollment was halted by the steering committee after the presentation of the MR CLEAN study at the World Stroke Congress because of the concern that providing intravenous recombinant-tPA alone would be unethical. 6 Final termination was decided on February 13, 2015 after the presentation and subsequent publication of 3 additional randomized trials that established endovascular therapy, in addition to intravenous recombinant-tPA, as standard of care.
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Patient Characteristics
We randomized 108 patients with ischemic stroke (53 intravenous and 55 IAT) between March 2012 and October 2014, across 36 US and German centers. Ninety-day outcome data were available in 96 patients (46 intravenous and 50 IAT; Figure  I in the online-only Data Supplement). PP analysis included 78 patients (41 intravenous and 37 IAT; Figure II in the online-only Data Supplement). As-treated analysis included 105 patients (62 intravenous and 43 IAT; Figure III in the online-only Data Supplement). Patients' baseline characteristics are provided in the Materials section in the online-only Data Supplement; Table  I in the online-only Data Supplement. Notable but nonsignificant differences occurred between intravenous-alteplase and thrombectomy cohorts with respect to female sex (57% versus 38%), history of atrial fibrillation (49% versus 33%), smoking history (39% versus 60%), and intracranial ICA occlusions (23% versus 33%). Both cohorts included patients with intermediate to severe early ischemic changes on baseline CT scan: 27 of 54 (50%) IAT patients with ASPECTS of ≤7, with 6 of 54 (11%) being ≤4, and 23 of 53 (44%) intravenous patients with ASPECTS of ≤7, with 4 of 53 (8%) being ≤4 (Table 1 ).
Intervention Details
Among 55 patients randomized to ITT, traditional separatorbased aspiration system (Penumbra) was used in 30 patients (54%), the separator 3D in 14 patients (25%), the ACE catheter (Penumbra) in 15 patients (27%), and either a Solitaire (Covidien) or a Trevo (Stryker) was used in 7 patients (13%). Successful reperfusion (modified thrombolysis in cerebral ischemia 2b/3) was achieved in 30 (70%) of 43 patients treated with only the Penumbra system (95% confidence interval [CI], 54-83) after aspiration thrombectomy alone. Inclusion of thrombectomy attempts with other devices (7 patients) resulted in a final modified thrombolysis in cerebral ischemia 2b/3 in 33 (73%) of 45 patients (95% CI, 58-85); 2 of these 7 stent-retriever patients underwent thrombectomy without attempted aspiration. General anesthesia was used in 29 of 45 (64%) patients who received any thrombectomy procedure. Further procedural details are provided in Table 2 . 
Secondary Outcomes
Rates of functional independence in the thrombectomy and intravenous-alteplase arms were also comparable (41% versus 29%; OR, 1.6; 95% CI, 0.6-4.2; P=0.30) in the PP analysis (Table 3) . Overall mRS distributions demonstrated better functional outcome for IAT in the PP analysis (OR, 2.2; 95% CI, 1.0-5.0; P=0.047) and a trend in the ITT analysis (OR, 1.8; 95% CI, 0.9-3.6; P=0.12; Figure 1 Figure 2A ). Secondary safety outcomes demonstrated no difference in the rates of sICH; 4 of 43 (9.3%) intravenous-alteplase plus thrombectomy versus 6 of 62 (9.7%) intravenous-alteplase alone (OR, 1.0; 95% CI, 0.3-3.9; Table 3 ). In addition, we observed comparable mortality rates with the direction of effect favoring aspiration thrombectomy in both ITT (12% thrombectomy versus 24% intravenous-alteplase; OR, 2.3; 95% CI, 0.8-6.8) and PP (7.3% thrombectomy versus 24% intravenous-alteplase; OR, 4.1; 95% CI, 1.0-16) analyses ( Figure IVa and IVb in the online-only Data Supplement).
Sensitivity Analysis
When assigning loss-to-follow-up patients with mRS score of 6, or when collapsing mRS score of 5 and 6 into a single ordinal category (Table IV in the online-only Data Supplement), the results remained consistent with the primary efficacy result.
Discussion
THERAPY sought to establish the benefit of aspiration thrombectomy in conjunction with intravenous-alteplase when compared with intravenous-alteplase alone in patients with a large anterior circulation proximal clot burden (≥8 mm), but it was halted early based on external evidence demonstrating the efficacy of thrombectomy. [6] [7] [8] [9] [10] Consequently, THERAPY was not powered to meet its predefined end points. Although the primary end point was not achieved, prespecified secondary end points suggest potential for benefit for aspiration thrombectomy ( Figure 2A ). In addition, although nonsignificant, the magnitude of potential treatment effect observed for the primary outcome measure is consistent with those of the recent positive thrombectomy trials ( Figure 2B ). Finally, similar to ESCAPE (The Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on In contrast to previous positive trials, THERAPY used the alternative thrombectomy technique of aspiration as the primary treatment modality. In MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment trial), and REVASCAT stent retrievers were primarily used (81.5%, 86%, 78%, 89%, and 100%, respectively), with or without aspiration, and it remained unclear whether stent retrievers were necessary to realize clinical benefit in this patient population. [6] [7] [8] [9] [10] Although early termination prevents a definitive answer, THERAPY supports the potential benefit of substantial revascularization from early thrombectomy by other means. Furthermore, the successful reperfusion rate (modified thrombolysis in cerebral ischemia 2b/3) of 73% (95% CI, 58-85) in a ≥8-mm clot burden population is consistent with the recently reported trials of MR CLEAN (59%), ESCAPE (72%), REVASCAT (65.7%), SWIFT PRIME (88%), and EXTEND-IA (86%). [6] [7] [8] [9] [10] However, aspiration thrombectomy has not directly been compared with stent retrievers, and, after the publication of these findings, only a prospective randomized trial of aspiration therapy versus stent-retriever thrombectomy can definitively answer this question.
Positive trials to date used highly variable approaches to patient selection. MR CLEAN included a broad range of patients and then allowed for clinical judgment to enroll the patient based on the gray area principle. 6 REVASCAT required a small, irreversibly injured ischemic core (ie, higher ASPECTS score) for the majority of patients as assessed by standard CT scan (with the exception of older and later presentation patients).
10 EXTEND-IA and SWIFT PRIME also selected for the presence of a potentially large salvageable ischemic penumbra. 8, 9 ESCAPE required the presence of a favorable collateral status. 7 These diverse approaches leave the key question of how to best select patients for endovascular therapy. Our findings, when considered along with REVASCAT and possibly MR CLEAN, suggest that noncontrast CT scan may be sufficient for evaluating the brain parenchyma (Table 4) . 6, 10 Advanced imaging such as CT or MR perfusion or multiphasic CT angiography collateral assessment, while selecting patients with favorable physiology, may exclude patients who would 
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still have a relative benefit from endovascular therapy. Planned prespecified pooled analyses of data from these 3 trials will likely delineate optimal patient selection approaches in a more definitive manner. 24 We also look forward to possible future pooled analysis of perfusion selection data from those studies that used perfusion imaging selection. Because THERAPY did not seek to evaluate the contribution of perfusion selection, these data were not collected.
In THERAPY, a large thrombus burden (≥8 mm in length) was a key enrollment criterion. Despite promising early publications 25 suggesting patients with such thrombi to be particularly resistant to intravenous-alteplase, our data do not seem to support this hypothesis. The good outcome rate in the intravenous-tPA alone cohort of THERAPY is consistent with estimates from broader cohorts of large vessel occlusion patients. Whether this discrepancy is secondary to limitations in sample size, measurement reliability (despite training), or lack of intravenous-tPA resistance at the 8-mm threshold remains to be elucidated.
Notably, although we observed no difference in the rate of sICH between the thrombectomy and intravenous-tPA alone cohorts, the overall rate of sICH in both arms was higher in THERAPY than in other recent trials (Table V in the online-only Data Supplement). This likely relates to varying definitions across trials. In THERAPY, sICH definition did not require relatedness to neurological decline, and it was, therefore, more inclusive. When using the published SWIFT PRIME definition, the sICH rate fell to 2.3% in the IAT cohort and 4.8% in the intravenous cohort (Table V in the online-only Data Supplement).
Not surprisingly, our small sample size led to imbalances in baseline characteristics (sex, history of atrial fibrillation, smoking status, and clot location) between the 2 treatment arms, despite randomization. Any and all of these imbalances may have affected outcome. However, most notable is clot location. Fewer intracranial ICA occlusion patients were in the intravenous arm (Table 1) , and they experienced only a 10% mRS score of 0 to 2 in the intravenous arm versus a 27% mRS score of 0 to 2 in the IAT arm. After accounting for these imbalances with prespecified (Table 3) .
THERAPY has several limitations. First, by focusing on a highly selected patient population, generalizability is limited. However, the numerically consistent effect sizes seen across all recent trials suggest potential benefit by varied selection criteria and treatment algorithms. Second, and most significantly, THERAPY was halted early and therefore findings are limited and their interpretations require caution.
In conclusion, THERAPY did not meet its primary end point in a limited sample size, but it did demonstrate a direction of effect toward benefit with both internal and external consistencies. It is possible that an alternate method of thrombectomy, primary aspiration, will benefit selected patients harboring large vessel occlusions. Further study on this topic is indicated.
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Antegrade reperfusion of more than half of the previously occluded target artery ischemic territory 3
Complete antegrade reperfusion of the previously occluded target artery ischemic territory, with absence of visualized occlusion in all distal branches mRS The modified Rankin Scale (mRS) is a measure of functional status and ranges from 0 (no symptoms) to 6 (death).
3
ASPECTS
The Alberta Stroke Program Early CT Score (ASPECTS) is a score from 0 to 10 which grades early ischemic change in specified 10 regions, with lower scores corresponding to larger infarcts.
ECASS
A follow-up noncontrast CT scan was performed at 24 ± 12 hours after randomization, and was reviewed to assess hemorrhagic transformation based on ECASS definitions 5 : · HI 1 (small petechiae along the margins of the infarcted area without space-occupying effect), · HI 2 (more confluent petechiae within the infarcted area but without space-occupying effect), · PH 1 (hematoma in <30% of the infarcted area with some slight space-occupying effect), · PH 2 (hematoma in >30% of infarcted area with substantial space-occupying effect). Based on previous work, only PH2 will be defined as a clinically significant hemorrhage. 6 In addition, any neurological deterioration should be evaluated by urgent CT scan and other evaluations as indicated according to investigator/hospital best practice. A symptomatic intracranial hemorrhage will be defined as 24 hour CT evidence of an ECASS defined ICH and a 4-point or more worsening of the NIHSS score.
SWIFT PRIME Symptomatic ICH Any PH1, PH2, RIH, SAH, or IVH associated with a 4 points or more worsening on the NIHSS within 24 hrs (± 3 hours). Penumbra System + IV tPA n=43
Allocation: IV tPA alone (n=53)
IV tPA alone n=53
Penumbra System + IV tPA (n=43) IV tPA alone (n=62) 
